$1.21 Billion is the total value of Casdin Capital, LLC's 41 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EQRX INC | $76,683,678 | -21.1% | 39,527,669 | 0.0% | 6.32% | -16.2% | ||
| PLRX | PLIANT THERAPEUTICS INC | $44,555,000 | +37.6% | 1,675,000 | 0.0% | 3.67% | +46.3% | |
| EXAS | EXACT SCIENCES CORP | $38,312,650 | +37.0% | 565,000 | 0.0% | 3.16% | +45.6% | |
| SOMALOGIC INC | $32,140,901 | +1.6% | 12,604,275 | 0.0% | 2.65% | +8.0% | ||
| DNLI | DENALI THERAPEUTICS INC | $29,952,000 | -17.2% | 1,300,000 | 0.0% | 2.47% | -11.9% | |
| TENAYA THERAPEUTICS INC | $17,324,751 | +41.8% | 6,078,860 | 0.0% | 1.43% | +50.7% | ||
| RXDX | PROMETHEUS BIOSCIENCES INC | $16,098,000 | -2.4% | 150,000 | 0.0% | 1.33% | +3.8% | |
| RNA | AVIDITY BIOSCIENCES INC | $13,047,500 | -30.8% | 850,000 | 0.0% | 1.08% | -26.4% | |
| FATE | FATE THERAPEUTICS INC | $11,685,000 | -43.5% | 2,050,000 | 0.0% | 0.96% | -39.9% | |
| IPSC | CENTURY THERAPEUTICS INC | $11,126,139 | -32.4% | 3,206,380 | 0.0% | 0.92% | -28.1% | |
| PRIME MEDICINE INC | $9,032,505 | -33.8% | 734,350 | 0.0% | 0.74% | -29.6% | ||
| INCY | INCYTE CORP | $5,600,925 | -10.0% | 77,500 | 0.0% | 0.46% | -4.4% | |
| GLUE | MONTE ROSA THERAPEUTICS INC | $3,979,771 | +2.4% | 510,882 | 0.0% | 0.33% | +9.0% | |
| OMIC | SINGULAR GENOMICS SYSTEMS IN | $1,628,324 | -39.8% | 1,345,722 | 0.0% | 0.13% | -36.2% | |
| EXSCIENTIA PLCads | $1,133,670 | -0.6% | 213,900 | 0.0% | 0.09% | +5.7% | ||
| LIANBIOsponsored ads | $402,509 | +18.9% | 206,415 | 0.0% | 0.03% | +26.9% | ||
| KRON | KRONOS BIO INC | $180,805 | -9.9% | 123,839 | 0.0% | 0.02% | -6.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-05 |
| SC 13D/A | 2024-06-03 |
| 4 | 2024-05-31 |
| 4 | 2024-05-28 |
| 4 | 2024-05-28 |
| 4 | 2024-05-22 |
| SC 13D/A | 2024-05-22 |
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-15 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.